Every Form 4 that Definium Therapeutics, Inc. (DFTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DFTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DFTX filings page.
Definium Therapeutics, Inc. (DFTX) reported that Chief Executive Officer and director Robert Barrow received an award of 40,000 common shares on September 2, 2026, representing the first tranche of performance share units originally granted effective February 3, 2026, which vest based on specified clinical and regulatory milestones. This amount also includes 417 shares acquired under the company’s 2024 Employee Share Purchase Plan on August 17, 2026.
On September 3, 2026, Barrow sold 19,023 common shares to satisfy withholding tax obligations related to the settlement of vested performance restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022. The reported weighted average sales price was $37.94 per share, with individual trades executed between $37.46 and $38.94 per share.
Definium Therapeutics, Inc. reported that Chief Executive Officer Robert Barrow acquired 375,000 common shares as a grant/award at a price of $0.0000 per share. The award represents the second tranche of performance share units granted effective March 12, 2025, and remains subject to vesting based on continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones. Following this award, Barrow directly holds 1,473,246 common shares.
Karlin Daniel reported acquisition or exercise transactions in this Form 4 filing.
Definium Therapeutics, Inc. reported that Chief Medical Officer Daniel Karlin received a grant of 100,000 Common Shares at a price of $0.00 per share. These shares represent the second tranche of performance share units originally granted effective March 12, 2025, and remain subject to vesting based on continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones under the Performance Share Unit Award Agreement. Following this award, Karlin directly holds 603,282 Common Shares.
Definium Therapeutics, Inc. reported that Chief Legal Officer Mark Sullivan acquired 62,500 common shares on August 12, 2026, at a stated price of $0.00 per share, increasing his direct holdings to 383,071 shares. According to the award terms, these shares represent the second tranche of performance share units granted effective March 12, 2025 and remain subject to vesting based on continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones.
Definium Therapeutics, Inc. reported that Chief Commercial Officer Matthew T. Wiley acquired 62,500 common shares as a grant/award. According to the award terms, these shares represent the second tranche of performance share units granted effective March 17, 2025 and remain subject to vesting based on continued employment through March 17, 2028 and the achievement of specified clinical and regulatory milestones. Following this award, Wiley holds 237,133 common shares directly.
Roberts Brandi reported acquisition or exercise transactions in this Form 4 filing.
Definium Therapeutics, Inc. reported that Chief Financial Officer Brandi Roberts received a grant of 62,500 Common Shares on August 12, 2026, at a stated price of $0.00 per share as a grant or award. After this award, Roberts directly holds 271,987 Common Shares. The shares represent the second tranche of performance share units originally granted effective June 2, 2025, and remain subject to vesting based on continued employment through June 2, 2028 and the achievement of specified clinical and regulatory milestones.
Definium Therapeutics, Inc. Chief Legal Officer Mark Sullivan reported an open-market sale of 13,008 Common Shares on June 25, 2026 at $45.03 per share. According to the footnote, these shares were sold to satisfy withholding tax obligations tied to the settlement of vested restricted stock units under sell-to-cover elections in a Rule 10b5-1 plan adopted on March 14, 2024. Following this transaction, Sullivan directly holds 320,571 Common Shares, indicating a continuing substantial equity position.
Definium Therapeutics Chief Financial Officer Brandi Roberts reported a small share sale tied to tax withholding. On June 25, 2026, she disposed of 3,013 common shares of Definium Therapeutics at $45.03 per share to satisfy withholding taxes from vested restricted stock units.
The transaction was executed under a previously adopted Rule 10b5-1 trading plan and represents a sell-to-cover event rather than a discretionary open-market sale. After this transaction, Roberts directly beneficially owns 209,487 common shares of the company.
Definium Therapeutics, Inc. Chief Executive Officer Robert Barrow sold 29,208 Common Shares at $45.03 per share on June 25, 2026. According to the disclosure, these shares were sold to satisfy withholding tax obligations tied to vested restricted stock units under a sell-to-cover election in a Rule 10b5-1 plan. Following this tax-related transaction, Barrow directly holds 1,098,246 Common Shares.
Definium Therapeutics, Inc. Chief Medical Officer Karlin Daniel sold 10,035 Common Shares of DFTX on June 25, 2026 at an average price of $45.03 per share. A footnote explains the shares were sold to satisfy withholding tax obligations upon settlement of vested restricted stock units under sell-to-cover elections in a Rule 10b5-1 plan adopted on June 14, 2022. Following this tax-related transaction, Daniel directly holds 503,282 Common Shares.
Definium Therapeutics, Inc. Chief Commercial Officer Wiley Matthew T. reported the sale of 2,867 Common Shares on June 25, 2026 at an average price of $45.03 per share. According to the footnote, these shares were sold to satisfy withholding tax obligations tied to the settlement of vested restricted stock units under a sell-to-cover election.
The transaction was carried out pursuant to a pre-adopted Rule 10b5-1 trading plan dated May 29, 2025, indicating it was pre-planned rather than a discretionary trade. Following this tax-related sale, Wiley beneficially owns 174,633 Common Shares directly, so the number of shares sold represents a small portion of his overall holdings.
Wiley Matthew T. reported acquisition or exercise transactions in this Form 4 filing.
Definium Therapeutics, Inc. reported that Chief Commercial Officer Matthew T. Wiley received an award of 62,500 common shares at no purchase price as part of his equity compensation. After this grant, he directly holds 177,500 common shares.
According to the footnote, these shares represent the first tranche of performance share units granted effective March 17, 2025. They remain subject to vesting based on his continued employment through March 17, 2028 and achievement of specified clinical and regulatory milestones under the Performance Share Unit Award Agreement.
Barrow Robert reported acquisition or exercise transactions in this Form 4 filing.
Definium Therapeutics, Inc. reported that Chief Executive Officer Robert Barrow received a grant of 375,000 common shares as a stock award, with no cash paid per share. Following this award, he directly holds 1,127,454 common shares.
The shares represent the first tranche of performance share units originally granted effective March 12, 2025. They remain subject to vesting based on his continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones.
Roberts Brandi reported acquisition or exercise transactions in this Form 4 filing.
Definium Therapeutics, Inc. Chief Financial Officer Brandi Roberts reported an equity compensation grant of 62,500 common shares at a price of $0.00 per share. These shares represent the first tranche of performance share units granted effective June 2, 2025.
The units remain subject to vesting based on her continued employment through June 2, 2028 and the achievement of specified clinical and regulatory milestones in the Performance Share Unit Award Agreement. Following this award, Roberts directly holds 212,500 common shares.
Sullivan Mark reported acquisition or exercise transactions in this Form 4 filing.
Definium Therapeutics Chief Legal Officer Mark Sullivan received 62,500 common shares as a performance-based equity award. The shares were granted at no purchase price and increase his direct holdings to 333,579 common shares. This tranche stems from performance share units granted effective March 12, 2025 and remains subject to vesting based on continued employment through March 12, 2028 and achievement of specified clinical and regulatory milestones.
Definium Therapeutics, Inc. reported that Chief Medical Officer Karlin Daniel received an award of 100,000 common shares at a price of $0.00 per share, classified as a grant or award acquisition. Following this transaction, he directly holds 513,317 common shares.
According to the footnote, these common shares represent the first tranche of performance share units granted effective March 12, 2025. They remain subject to vesting based on Daniel’s continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones under the Performance Share Unit Award Agreement.
Definium Therapeutics director Crystal Roger received new equity awards as part of her compensation. She was granted 4,666 restricted stock units, each representing the right to receive one common share, and now holds 24,289 common shares after this award.
Roger was also granted a stock option covering 19,188 common shares at an exercise price of $24.11 per share, expiring on June 10, 2036. Both the RSUs and the option vest as to 1/12 of the underlying shares on each monthly anniversary of the grant date, with any remaining unvested portion vesting immediately before the company’s next annual meeting if it occurs within a year, subject to her continued service.
Definium Therapeutics director David W. Gryska received equity awards as part of his compensation. He was granted 4,666 restricted stock units, each representing one common share, and now holds 19,900 common shares directly after this grant. The filing also reports a grant of stock options for 19,188 common shares at an exercise price of $24.11 per share, expiring on June 10, 2036.
The restricted stock units and options each vest as to 1/12 of the underlying shares on every monthly anniversary of the grant date. If the company’s first annual meeting after the grant occurs before the first anniversary, any remaining unvested RSUs and options will vest immediately before that meeting, subject to his continued service.
Definium Therapeutics director Carol A. Vallone received equity-based compensation consisting of restricted stock units and stock options. She was granted 4,666 RSUs, each representing one common share at no purchase price, bringing her direct holdings to 21,210 common shares.
Vallone also received a stock option covering 19,188 common shares at an exercise price of $24.11 per share, expiring on June 10, 2036. Both the RSUs and the option vest in 12 equal monthly installments from the grant date, with any remaining unvested portion vesting earlier immediately before the issuer’s next annual meeting if it occurs within the first year, subject to her continued service.
Definium Therapeutics director Andreas Krebs received new equity awards. He was granted 4,666 restricted stock units, each representing one common share, and a stock option covering 19,188 common shares at an exercise price of $24.11 per share. Following the award, he directly holds 19,773 common shares, and the option vests in 12 equal monthly installments, with both the RSUs and option subject to possible acceleration immediately before the next annual meeting if it occurs within one year of grant and he continues in service.
Definium Therapeutics director Roger Adsett reported equity awards consisting of 3,555 common shares in the form of restricted stock units and 14,620 stock options. The options carry an exercise price of $24.11 per share and expire on June 10, 2036.
Both the RSUs and options vest as to 1/12 of the underlying shares on each monthly anniversary of the grant date, with any remaining unvested portion vesting immediately before the issuer’s next annual meeting if it occurs before the first anniversary, subject to his continued service. Following these grants, Adsett holds 3,555 common shares and 14,620 options directly.
Definium Therapeutics director Suzanne Louise Bruhn received equity compensation on common shares. She was granted 4,666 restricted stock units, each representing one future common share, and a stock option for 19,188 common shares at an exercise price of $24.11 per share.
The RSUs and the stock option each vest as to 1/12 of the underlying shares on each monthly anniversary of the grant date, with remaining unvested awards vesting immediately before the company’s next annual meeting if it occurs within the first year, subject to her continued service. Following these grants, she directly holds 24,289 common shares.
Definium Therapeutics, Inc. Chief Medical Officer Daniel Karlin reported an open-market sale of 8,018 Common Shares on March 25, 2026 at a weighted average price of $18.47 per share. According to the footnotes, these shares were sold to satisfy withholding tax obligations tied to the settlement of vested restricted stock units under a Rule 10b5-1 sell-to-cover plan adopted on June 14, 2022.
After this transaction, Karlin directly owns 413,317 Common Shares, which includes 1,586 shares acquired through the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan. This filing reflects a tax-related, pre-planned disposition rather than a discretionary sale of a large ownership stake.
Definium Therapeutics, Inc. Chief Legal Officer Mark Sullivan sold 10,702 Common Shares on March 25, 2026 at a weighted average price of $18.47. According to the filing, the shares were sold to satisfy withholding tax obligations tied to vested restricted stock units under a Rule 10b5-1 sell-to-cover plan adopted on March 14, 2024. Following this tax-related sale, he directly holds 271,079 Common Shares, which includes 793 shares acquired under the company’s 2024 Employee Share Purchase Plan.
Definium Therapeutics, Inc. Chief Executive Officer Robert Barrow reported an open-market sale of 24,431 Common Shares at a weighted average price of $18.47 per share. The shares were sold to satisfy withholding tax obligations linked to vested restricted stock units under a Rule 10b5-1 sell-to-cover plan adopted on June 15, 2022.
Following this transaction, Barrow directly holds 752,454 Common Shares, and this amount includes 1,586 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan. Because the sale was for tax withholding under a pre-planned trading arrangement, it reflects a routine administrative event rather than a discretionary change in ownership.
Definium Therapeutics, Inc. granted its Chief Commercial Officer, Matthew T. Wiley, 115,000 common shares in the form of restricted stock units (RSUs). The grant was reported as an acquisition at a price of $0.00 per share, held directly by the officer.
Each RSU represents a contingent right to receive one common share of Definium Therapeutics. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, as long as Wiley continues providing service to the company on each vesting date.
Definium Therapeutics, Inc. granted its Chief Financial Officer, Brandi Roberts, an award of 150,000 restricted stock units (RSUs). Each RSU represents the right to receive one common share.
The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, as long as Roberts continues providing service on each vesting date. The award was reported as a direct, no-cost acquisition, with 150,000 common shares beneficially owned following the transaction.
Definium Therapeutics, Inc. Chief Legal Officer Mark Sullivan reported an equity award of 125,000 common shares in the form of restricted stock units on February 3, 2026. The award was granted at a price of $0.00 per share as part of his compensation.
Each RSU represents a right to receive one common share, vesting in 16 equal quarterly installments beginning June 1, 2026, so long as he continues providing service on each vesting date. Following this grant, he beneficially owns 407,576 common shares directly.
Definium Therapeutics, Inc. Chief Medical Officer Dan Karlin reported an award of 150,000 common shares of the company on February 3, 2026. These are structured as restricted stock units, granted at a price of $0.00 per share, increasing his direct holdings to 575,025 shares.
The RSUs vest in 16 equal quarterly installments starting on June 1, 2026. Each RSU converts into one common share if he continues providing service to Definium Therapeutics on each vesting date, tying the value of this grant to his ongoing tenure.
Definium Therapeutics, Inc. reported that Chief Executive Officer and director Robert Barrow received an award of 320,000 restricted stock units (RSUs), each representing one common share. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026. After this grant, Barrow beneficially owns 1,098,477 common shares of Definium Therapeutics.
Definium Therapeutics director Roger Adsett received a grant of stock options on 01/29/2026. The award covers options to buy 50,000 common shares at an exercise price of $17.24 per share, all held directly.
The options vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in 24 equal monthly installments, contingent on Mr. Adsett’s continued service to the company.